Skip to main content
spacbrain

Science 37 Holdings

Closed (deSPAC)

Health Care · decentralized clinical trial platform

What it is
Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients
What it’s doing now
Merging with Lifesci Acquisition II Corp. (LSAQ) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

Science 37 Holdings, Inc.’s (Nasdaq: SNCE) mission is to accelerate clinical research by enabling universal trial access for patients. Through our Metasite™ we reach an expanded population beyond the traditional site, delivering on our goal of clinical research that works for everyone—with greater patient diversity. Patients gain the flexibility to participate from the comfort of their own homes, at their local community provider, or at a traditional site when needed. Our Metasite™ is powered by a proprietary technology platform with in-house medical and operational experts that drive uniform study orchestration, enabling greater compliance and high-quality data. To learn more, visit www.science37.com, or email science37@science37.com. About eMed: eMed is a telehealth and diagnostics company that develops a leading digital point-of-care platform designed for complete testing processes to be done at home. The company's platform provides verified test results and access to on-demand prescription treatment with same-day delivery, enabling consumers to easily get tested and receive expert healthcare guidance. eMed developed the first at-home, digital point-of-care COVID-19 test in 2020. The company has expanded its offering of kits since then to include testing for the flu and UTIs, among others –supported by its on-demand telehealth solutions. Cautionary Note Regarding

Source: S-4/A, accession 0001104659-21-111682

What the company says about itself

Web research — not audited

Science 37 is an industry-leading patient access company and modern clinical research site that delivers clinical trials directly to patients' homes. Founded over a decade ago, it is the first and only FDA-inspected direct-to-patient site, supporting trial enrollment through patient- and site-centric solutions across a wide range of therapeutic areas.

Markets:
Cardiovascular | Central Nervous System | Dermatology | Endocrinology | Gastroenterology | Hematology | Immunology | Infectious Disease | Men's Health | Musculoskeletal | Oncology | Ophthalmology | Respiratory | Urology | Women's Health | Pediatrics
Products:
Direct-to-Patient Site | Patient Recruitment | Research-Grade Nursing
Customers:
Acer Therapeutics | Adrenas | Advarra | Anthos Therapeutics | Avillion | Bayer | Biohaven | Boehringer Ingelheim | Catalent | Chugai Pharmaceutical | Delfi | Escient Pharmaceuticals | GSK | Harmony Biosciences | Jazz Pharmaceuticals | LabConnect | Mirum Pharmaceuticals | PatientsLikeMe | PureTech Health | RxE2
What our web check found

[WEB-INTEL 2026-08-26] 1 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The merger delivers $235 million in cash to Science 37" [https://www.bizjournals.com/triangle/news/2021/10/07/science-37-completeses-spac-merger.html]

Source: https://www.science37.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

Science 37 Holdings is merging with Lifesci Acquisition II Corp. (LSAQ) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $200M · unsourced

Structure per SEC accession(s) 0001104659-21-096507, 0001104659-24-007463. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is Science 37 Holdings going public?

Science 37 Holdings has an approved merger with the SPAC Lifesci Acquisition II Corp. (LSAQ). Deal status: Closed (deSPAC).

Does Science 37 Holdings have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals